Want to see SE:FLUI full AI Analyst Report?

Fluicell AB (FLUI) Price & Analysis

0 Followers

FLUI Stock Chart & Stats

kr10.00

>-kr0.01(-1.38%)

At close: Mar 06 4:00 PM EST

kr10.00

>-kr0.01(-1.38%)

Day’s Range― - ―

52-Week Rangekr7.65 - kr67.20

Previous CloseN/A

Volume175.18K

Average Volume (3M)7.51K

Market Cap

kr45.88M

Enterprise Valuekr43.46

Total Cash (Recent Filing)kr30.00K

Total Debt (Recent Filing)kr2.00M

Price to Earnings (P/E)16.3

Beta1.08

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.04

Shares Outstanding1,373,703

10 Day Avg. Volume8,127

30 Day Avg. Volume7,512

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.26

Price to Sales (P/S)2.29

P/FCF Ratio-1.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr68.60M

Bulls Say, Bears Say

Bulls Say

Revenue And Profitability InflectionThe sharp TTM revenue increase alongside positive EBIT and net income indicates meaningful operating progress and improving commercial traction. If this growth converts into repeatable earnings, Fluicell could gain greater capacity to reinvest in products, applications, and market development.

Very High Gross MarginA gross margin near 92% provides substantial economic headroom after direct product costs and can support investment in research, sales, and customer applications. Maintaining this level as revenue scales would strengthen the business model and improve the potential for durable operating profitability.

Modest Leverage And Improved Equity BaseLow debt relative to equity limits balance-sheet pressure and preserves financial flexibility compared with a highly leveraged structure. The stronger equity base also provides a larger cushion against setbacks, giving Fluicell more room to pursue development and commercialization without excessive debt dependence.

Bears Say

Negative Cash GenerationFluicell is not yet self-funding despite reporting positive net income, because operating cash flow remains slightly negative and free cash flow is materially below zero. Persistent annual cash burn can increase reliance on external financing and constrain the company’s ability to fund growth independently.

Long History Of LossesThe recent profitable TTM period has not yet overcome Fluicell’s multi-year record of substantial operating losses and negative returns. This history weakens confidence that earnings can remain positive through different development and commercialization conditions, making sustained execution an important requirement.

Profitability Durability RiskThe pack explicitly cautions that recent profitability and margin strength may be volatile given Fluicell’s small biotech scale. Until stronger results demonstrate repeatability as revenue expands, earnings quality remains less established and future operating performance may be uneven.

FLUI FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was kr7.65 and its highest was kr67.20 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is kr45.88M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is Nov 13, 2026 which is in 59 days.

How were Fluicell AB’s earnings last quarter?

Fluicell AB released its earnings results on Aug 28, 2026. The company reported kr1.645 earnings per share for the quarter.

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Fluicell AB reported an EPS of kr1.645 in its last earnings report. Following the earnings report the stock price went down -11.389%.

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in SE:FLUI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.